First Light Asset Management LLC Grows Stake in Omnicell, Inc. (OMCL)
First Light Asset Management LLC lifted its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 6.5% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 338,113 shares of the company’s stock after buying an additional 20,782 shares during the quarter. Omnicell makes up about 3.2% of First Light Asset Management LLC’s holdings, making the stock its 12th largest position. First Light Asset Management LLC owned about 0.87% of Omnicell worth $14,674,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in OMCL. SG Americas Securities LLC acquired a new position in shares of Omnicell during the 1st quarter worth $116,000. Pitcairn Co. acquired a new position in Omnicell in the 1st quarter valued at about $203,000. Oppenheimer Asset Management Inc. acquired a new position in Omnicell in the 1st quarter valued at about $223,000. Elkfork Partners LLC acquired a new position in Omnicell in the 4th quarter valued at about $225,000. Finally, Jane Street Group LLC acquired a new position in Omnicell in the 1st quarter valued at about $237,000. 99.99% of the stock is owned by institutional investors and hedge funds.
In other news, insider Peter J. Kuipers sold 9,144 shares of the company’s stock in a transaction dated Wednesday, June 6th. The shares were sold at an average price of $49.57, for a total transaction of $453,268.08. Following the completion of the transaction, the insider now owns 56,970 shares of the company’s stock, valued at approximately $2,824,002.90. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Peter J. Kuipers sold 724 shares of the company’s stock in a transaction dated Thursday, April 12th. The shares were sold at an average price of $46.00, for a total transaction of $33,304.00. Following the transaction, the insider now directly owns 56,970 shares of the company’s stock, valued at approximately $2,620,620. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 55,202 shares of company stock valued at $2,603,594. Corporate insiders own 3.71% of the company’s stock.
Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, April 26th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.04. Omnicell had a net margin of 4.55% and a return on equity of 4.11%. The firm had revenue of $182.60 million during the quarter, compared to the consensus estimate of $177.49 million. During the same quarter in the previous year, the company posted $0.06 EPS. The firm’s revenue for the quarter was up 22.9% on a year-over-year basis. analysts expect that Omnicell, Inc. will post 1.38 EPS for the current year.
OMCL has been the subject of several analyst reports. Cantor Fitzgerald reissued a “buy” rating and issued a $63.00 target price on shares of Omnicell in a research note on Tuesday, April 3rd. BidaskClub downgraded shares of Omnicell from a “hold” rating to a “sell” rating in a research note on Friday, April 20th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $56.67.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.